Home | Validate

Amount in (Millions)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.

Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Details of the loans, inter-corporate deposits, advances or investments					
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	Notes
Add / Delete																								
1	Gland Pharma Limited		Avanc Pharma Distribution Co Ltd		Fellow subsidiary	Sale of goods or services		200.00	NA			0.00	0.00	0.00										
2	Gland Pharma Limited		Avanc Pharma Distribution Co. Ltd		Fellow subsidiary	Sale of goods or services		20.00	NA			0.00	0.00	0.00										
3	Gland Pharma Limited		Avanc Pharmaceutical Co., Ltd		Fellow subsidiary	Sale of goods or services		20.00	NA			0.00	0.00	0.00										
4	Gland Pharma Limited		Chongqing Carelife Pharmaceutical Co., Ltd		Fellow subsidiary	Purchase of goods or services		297.50	NA			43.65	0.00	0.00										
5	Gland Pharma Limited		Chongqing Carelife Pharmaceutical Co., Ltd		Fellow subsidiary	Any other transaction	Reimbursement of Expenses	15.00	NA			0.00	-51.67	0.00										
6	Gland Pharma Limited		Fosun Pharma USA Inc.		Fellow subsidiary	Any other transaction	Reimbursement of Expenses	150.00	NA			140.13	0.00	0.00										
7	Gland Pharma Limited		Fosun Pharma USA Inc.		Fellow subsidiary	Sale of goods or services		4000.00	NA			1277.20	1167.75	1183.43										
8	Gland Pharma Limited		Fosun Pharma USA Inc.		Fellow subsidiary	Sale of goods or services		600.00	NA			197.13	0.00	0.00										
9	Gland Pharma Limited		Gland Pharma International Pte Ltd.		Wholly Owned Subsidiary	Sale of goods or services		2500.00	NA			864.38	298.65	176.67										
10	Gland Pharma Limited		Gland Pharma International Pte Ltd.		Wholly Owned Subsidiary	Sale of goods or services		100.00	NA			0.00	0.00	0.00										
11	Gland Pharma Limited		Gland Pharma International Pte Ltd.		Wholly Owned Subsidiary	Any other transaction	Reimbursement of Expenses	100.00	NA			0.00	0.00	0.00										
12	Gland Pharma Limited		Gland Pharma USA INC.		Wholly Owned Subsidiary	Sale of goods or services		50.00	NA			0.00	0.00	0.00										
13	Gland Pharma Limited		Gland Pharma USA INC.		Wholly Owned Subsidiary	Any other transaction	Reimbursement of Expenses	50.00	NA			0.00	0.00	0.00										
14	Gland Pharma Limited		Gland Pharma USA INC.		Wholly Owned Subsidiary	Any other transaction	Selling and Business Promotion Expenses	50.00	NA			0.00	0.00	0.00										
15	Gland Pharma Limited		Gland Pharma International Pte Ltd.		Wholly Owned Subsidiary	Investment		6300.00	NA			5029.85	0.00	0.00										
16	Gland Pharma Limited		Suzhou Eye Pharmaceutical Co. Ltd		Fellow subsidiary	Purchase of goods or services		408.00	NA			0.00	0.00	0.00										
17	Gland Pharma Limited		Suzhou Eye Pharmaceutical Co. Ltd		Fellow subsidiary	Any other transaction	Reimbursement of Expenses	5.00	NA			0.00	1.35	0.00										
18	Gland Pharma Limited		Tridem Pharma SAS		Fellow subsidiary	Sale of goods or services		100.00	NA			0.00	0.00	0.00										
19	Gland Pharma Limited		Fosun Wanbang (Jiangsu) Pharmaceutical Group CO., LTD. Formerly known as Wanbang Biopharmaceuticals)		Fellow subsidiary	Purchase of goods or services		2560.00	NA			724.24	0.00	-111.56										
20	Gland Pharma Limited		Fosun Wanbang (Jiangsu) Pharmaceutical Group CO., LTD. Formerly known as Wanbang Biopharmaceuticals)		Fellow subsidiary	Any other transaction	Reimbursement of Expenses	15.00	NA			0.00	0.00	0.00										
21	Gland Pharma Limited		Jiangsu Wanbang Helios International Trade Co. Ltd.		Fellow subsidiary	Sale of goods or services		100.00	NA			3.41	0.00	0.00										
22	Gland Pharma Limited		Jiangsu Wanbang Helios International Trade Co. Ltd.		Fellow subsidiary	Purchase of goods or services		1275.00	NA			0.00	0.00	0.00										
23	Gland Pharma Limited		Tridem Pharma Tanzania Limited		Fellow subsidiary	Sale of goods or services		34.00	NA			0.00	4.58	0.00										
24	Gland Pharma Limited		Tridem Pharma Tanzania Limited		Fellow subsidiary	Any other transaction	Reimbursement of Expenses	5.00	NA			0.00	0.00	0.00										
25	Gland Pharma Limited		Phixen SAS and its subsidiaries		Wholly owned step-down subsidiaries	Sale of goods or services		450.00	NA			0.00	0.00	0.00										
26	Gland Pharma Limited		Phixen SAS and its subsidiaries		Wholly owned step-down subsidiaries	Sale of goods or services		450.00	NA			0.00	0.00	0.00										
27	Gland Pharma Limited		Phixen SAS and its subsidiaries		Wholly owned step-down subsidiaries	Purchase of goods or services		450.00	NA			0.00	0.00	0.00										
28	Gland Pharma Limited		Phixen SAS and its subsidiaries		Wholly owned step-down subsidiaries	Purchase of goods or services		450.00	NA			0.00	0.00	0.00										
29	Gland Pharma Limited		Phixen SAS and its subsidiaries		Wholly owned step-down subsidiaries	Any other transaction	Reimbursement of Expenses	90.00	NA			0.00	0.00	0.00										
30	Gland Pharma Limited		Shanghai Fosun Pharmaceutical Industrial Development Co Ltd		Fellow subsidiary	Purchase of goods or services		15.00	NA			5.51	-10.61	-15.43										
31	Gland Pharma Limited		Aton (Shanghai) Biotech Co., Ltd		Fellow subsidiary	Any other transaction	collection of expenses paid on their behalf	15.00	NA			0.00	0.00	0.00										
32	Gland Pharma Limited		Shanghai Fosun Pharmaceutical (Group) Co Ltd		Ultimate Holding Company	Any other transaction	Reimbursement of Expenses	3.50	NA			0.00	0.00	0.00										
33	Gland Pharma Limited		Shanghai Henlius Biotech Inc.		Fellow subsidiary	Any other transaction	Reimbursement of Expenses	15.00	NA			0.00	13.54	0.00										
34	Gland Pharma Limited		Hunan Dongting Pharmaceutical Co. Ltd		Fellow subsidiary	Any other transaction	collection of expenses paid on their behalf	5.00	NA			0.00	1.35	0.00										
35	Gland Pharma Limited		Phixen SAS and its subsidiaries		Wholly owned step-down subsidiaries	Investment		8100.00	NA			0.00	0.00	0.00										
36	Gland Pharma Limited		Hunan Dongting Pharmaceutical Co. Ltd		Fellow subsidiary	Purchase of goods or services		100.00	NA			19.04	0.00	0.00										
37	Gland Pharma Limited		Fosun Pharma SAS		Fellow subsidiary	Sale of goods or services		425.00	NA			11.68	0.00	11.15										
38	Gland Pharma Limited		Fosun Pharma SAS		Fellow subsidiary	Sale of goods or services		85.00	NA			0.00	0.00	0.00										
39	Gland Pharma Limited		Fosun Pharma SAS		Fellow subsidiary	Any other transaction	Reimbursement of Expenses	85.00	NA			0.00	0.00	0.00										
40	Gland Pharma Limited		Suzhou Eye Pharmaceutical Co. Ltd.		Fellow subsidiary	Sale of goods or services		50.00	NA			0.00	0.00	0.00										
41	Gland Pharma Limited		Srinivas Sadu		Key management personnel	Remuneration		109.09	NA			109.09	-16.77	-10.14										
42	Gland Pharma International Pte Ltd.		Srinivas Sadu		Key management personnel	Remuneration		17.03	NA			17.03	-1.36	0.00										
43	Gland Pharma Limited		Ravi Shekhar Mitra		Key management personnel	Remuneration		48.36	NA			48.36	0.00	-5.18										
44	Gland Pharma International Pte Ltd.		Ravi Shekhar Mitra		Key management personnel	Remuneration		0.00	NA			0.00	-7.52	0.00										
45	Gland Pharma Limited		Shyamakant Giri		Key management personnel	Any other transaction	Sitting Fees	37.57	NA			37.57	-5.00	-15.00										
46	Gland Pharma Limited		Satyanarayana Murthy Chavali		Director	Any other transaction	Sitting Fees	1.10	NA			1.10	0.00	0.00										
47	Gland Pharma Limited		Satyanarayana Murthy Chavali		Director	Any other transaction	Commission	3.25	NA			3.25	-2.25	-3.25										
48	Gland Pharma International Pte Ltd.		Satyanarayana Murthy Chavali		Director	Remuneration		0.69	NA			0.69	-1.69	-0.69										
49	Gland Pharma Limited		Lido J. Vetter		Key management personnel	Any other transaction	Sitting Fees	0.90	NA			0.90	0.00	0.00										
50	Gland Pharma Limited		Lido J. Vetter		Key management personnel	Any other transaction	Commission	1.25	NA			1.25	-1.72	-1.25										
51	Gland Pharma Limited		Essaji Gosiam Vahanvati		Key management personnel	Any other transaction	Sitting Fees	0.80	NA			0.80	0.00	0.00										
52	Gland Pharma Limited		Essaji Gosiam Vahanvati		Key management personnel	Any other transaction	Commission	1.25	NA			1.25	-2.25	-1.25										
53	Gland Pharma Limited		Nainalal Kidwai		Key management personnel	Any other transaction	Sitting Fees	0.40	NA			0.40	0.00	0.00										
54	Gland Pharma Limited		Nainalal Kidwai		Key management personnel	Any other transaction	Commision	5.00	NA			5.00	-9.00	-5.00										
55	Gland Pharma Limited		P. Sarvesh Kumar		Key management personnel	Remuneration		8.57	NA			8.57	-1.64	-0.98										
Total value of transaction during the reporting period												8549.49												

Notes:

1. The details in this format are required to be provided for all transactions undertaken during the reporting period. However, opening and closing balances, including commitments, to be disclosed for existing related party transactions even if there is no new related party transaction during the reporting period.
2. Where a transaction is undertaken between members of the consolidated entity (between the listed entity and its subsidiary or between subsidiaries), it may be reported once.
3. Listed banks shall not be required to provide the disclosures with respect to related party transactions involving loans, inter-corporate deposits, advances or investments made or given by the listed banks.
4. For companies with financial year ending March 31, this information has to be provided for six months ended September 30 and six months ended March 31.
Companies with financial years ending in other months, the six months period shall apply accordingly.
5. Each type of related party transaction (for e.g. sale of goods/services, purchase of goods/services or whether it involves a loan, inter-corporate deposit, advance or investment) with a single party shall be disclosed separately and there should be no clubbing or netting of transactions of same type.
However, transactions with the same counterparty of the same type may be aggregated for the reporting period. For instance, sale transactions with the same party may be aggregated for the reporting period and purchase transactions may also be disclosed in a similar manner. There should be no netting off for sale and purchase transactions. Similarly, loans advanced to and received from the same counterparty should be disclosed separately, without any netting off.
6. In case of a multi-year related party transaction:
   a. The aggregate value of such related party transaction as approved by the audit committee shall be disclosed in the column "Value of the related party transaction as approved by the audit committee".
   b. The value of the related party transaction ratified by the audit committee shall be disclosed in the column "Value of the related party transaction ratified by the audit committee".
   c. The value of the related party transaction undertaken in the reporting period shall be reported in the column "Value of related party transaction during the reporting period".
7. "Cost" refers to the cost of borrowed funds for the listed entity. 8. Transactions such as acceptance of fixed deposits by banks/NBFCs, undertaken with related parties, at the terms uniformly applicable /offered to all shareholders/ public shall also be reported.